Off-label use of targeted antineoplastic drugs
Numerous off-label uses in oncology show the need for new applications outside the previously authorised areas. In this exploratory study at Vienna General Hospital, the proportion of targeted, antineoplastic drugs prescribed to oncological patients outside their area of authorisation (‘off-label’) is being surveyed.
It is the most comprehensive study in Austria that provides a retrospective view of the use of such drugs. Conducted at the University Hospital AKH Vienna, it enables the largest possible population to be analysed and should provide information on the main areas of use of antineoplastic drugs.
The proportion of ‘off-label’ prescriptions will be broken down by active ingredient and indication and analysed statistically. The aim is to establish the need for scientific evidence in antineoplastic therapy in order to subsequently create the conditions for the targeted planning of clinical trials.
‘In cancer research, it is important to always think one step ahead. With this large-scale analysis study, we are creating a basis for further targeted clinical research in the field of antineoplastic drugs.’